Moleculin Biotech posts new corporate presentation
Moleculin Biotech, Inc. filed a current report to make investors aware that it is using an updated corporate presentation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Moleculin Biotech, Inc. filed a current report to make investors aware that it is using an updated corporate presentation. The company states that this presentation is posted on its website and is included as Exhibit 99.1.
The company clarifies that the information in this presentation is being furnished under a disclosure item and is not considered "filed" under securities laws, unless a future document specifically incorporates it by reference. This distinction affects how the information is treated for legal and liability purposes.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Moleculin Biotech, Inc. (MBRX) disclose in this 8-K filing?
Moleculin Biotech disclosed that it is using an updated corporate presentation for its communications. The presentation is posted on the company’s website and is included in the filing as Exhibit 99.1 for investor reference.
What is Exhibit 99.1 in Moleculin Biotech’s (MBRX) latest 8-K?
Exhibit 99.1 is the corporate presentation Moleculin Biotech is currently using. The company notes this presentation is available on its website and is furnished with the report rather than being formally filed under securities laws.
Is Moleculin Biotech’s (MBRX) corporate presentation considered "filed" with the SEC?
No, the company states the corporate presentation is being furnished, not filed, under securities regulations. It will only be treated as filed if a future document specifically identifies and incorporates it by reference into another registration or periodic report.
Why does Moleculin Biotech (MBRX) say the presentation is only "furnished"?
The company explains that the information, including Exhibit 99.1, is furnished under a disclosure item and not deemed filed. This limits how the material is treated for certain Exchange Act and Securities Act provisions unless later incorporated by reference.
Where can investors access Moleculin Biotech’s (MBRX) updated presentation?
Investors can access the updated corporate presentation on Moleculin Biotech’s website. The same presentation is also attached to the current report as Exhibit 99.1, giving investors another way to review the disclosed materials.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 18, 2026
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
(Commission File No.)
|
(I.R.S. Employer Identification No.)
|
(Address of principal executive offices and zip code)
(713 ) 300-5160
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol (s)
|
Name of each exchange on which registered
|
|
|
|
The
|
|
Item 7.01
|
Regulation FD Disclosure
|
On February 18, 2026, Moleculin Biotech, Inc. (the “Company”) is using the attached presentation for its corporate presentation posted on the Company’s website and is set forth as Exhibit 99.1 herein.
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
|
Exhibit No.
|
Description
|
|
99.1
|
Investor Presentation dated February 2026
|
|
104
|
Cover page Interactive Data File (formatted as Inline XBRL document)
|
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MOLECULIN BIOTECH, INC.
|
|||
|
Date:
|
February 18, 2026
|
||
|
By:
|
/s/ Jonathan P. Foster
|
||
|
Jonathan P. Foster
|
|||
Exhibit 99.1
